Ergothioneine, S-methyl-ergothioneine and uses thereof

By detecting the level of S-methyl-L-ergothione in urine and using ergothione treatment, the problem of diagnosis and treatment of cystine stones in cysturia patients was solved, early detection and long-term prevention were achieved, and the side effect.

CN114269722BActive Publication Date: 2024-11-22FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL) +2
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202080053768.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-07-26
Filing Date
2020-07-24
Publication Date
2024-11-22
Estimated Expiration
2040-07-24

AI Technical Summary

Technical Problem

The prior art is difficult to effectively diagnose and treat cystine stones in cysturia patients, and the existing drugs have side effects and poor treatment effects.

Method used

Cystine stones are diagnosed by detecting the levels of S-methyl-L-ergothionein (S-met-L-Erg) in the urine and using ergothionein (Erg) as a new therapy to prevent or delay cystine The formation of acid stones.

Benefits of technology

Early detection and effective prevention of cystine stones in cysturia patients has been achieved, which reduces side effects and improves the long-term effect of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003487579510000141
    Figure BDA0003487579510000141
  • Figure BDA0003487579510000151
    Figure BDA0003487579510000151
  • Figure HDA0003487579520000011
    Figure HDA0003487579520000011
Patent Text Reader

Abstract

The present invention provides S-methyl-L-ergothioneine for diagnosis and / or prognosis. The present invention also provides a method for diagnosis and / or prognosis of nephropathy, including a step of determining the amount of S-methyl-L-ergothioneine in a test sample separated from a subject, and a method for determining or recommending the initiation of a therapeutic intervention or for determining the efficacy of a therapeutic intervention. The present invention also provides ergothioneine for the treatment and / or prevention of kidney stones or aminoaciduria, and ergothioneine for combined therapy.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims the benefit of European patent application EP 19382644.3 filed on July 26, 2019. Technical Field

[0002] The present invention belongs to the field of medicine. In particular, it belongs to the field of nephropathy. The present invention provided herein is particularly suitable for diagnosing and treating cystine stones. Background Art

[0003] Cystinuria is a disorder with an autosomal recessive inheritance pattern characterized by the expression of the amino acid transporter rBAT / b 0,+ AT deficiency causes problems with renal reabsorption and intestinal absorption of cystine and aminodicarboxylic acids. Cystinuria develops into cystine stones, which are caused by the precipitation of cystine in the urinary system that forms stones. These stones can lead to obstruction, infection, and ultimately renal failure.

[0004] To date, two genes that cause cystinuria, SLC3A1 and SLC7A9, have been identified and encode the proteins responsible for 0,+ rBAT / b amino acid transport system 0,+ AT heteromeric complex. This is the main apical reabsorption system of cystine in the kidney. This transporter belongs to the heteromeric amino acid transporter (HAT) family, which consists of a heavy subunit (rBAT or 4F2hc) connected by disulfide bridges to a series of light subunits (in the case of rBAT, b 0,+ AT) is formed.

[0005] Cystinuria is diagnosed by demonstrating selective oversecretion of cystine and aminodicarboxylic acids in the urine. Hexagonal crystals appear in the urine of 20-25% of cystinuric patients, so the only proven clinical manifestation of cystinuria is cystine stones. In fact, up to 10% of all urinary stones in children are caused by cystinuria. More than 80% of cystinuric patients develop their first cystine stone within the first twenty years of life, 75% in both kidneys. Most patients suffer from recurrent stone formation throughout their lifetime, requiring repeated interventions. Currently, it is impossible to predict when a cystinuric patient will develop cystine stones. In addition, the only way to detect whether a patient has already formed stones is through complex imaging techniques such as KUB X-ray, computed tomography (CT) and ultrasound.

[0006] Human cystinuria is treated with high fluid intake, a low-salt diet (<2 g NaCl / day), modest reduction in protein intake (<0.8 g / day), and prevention of cystine stone formation by maximizing cystine solubility through alkalinization of the urine to a pH of at least 7.5 (with potassium citrate or sodium bicarbonate in cases of severe renal insufficiency). Even with medical management, long-term outcomes are poor due to inadequate efficacy and low patient compliance.

[0007] If prevention fails, the patient is treated to dissolve or break up the stones. Stones are removed by surgical nephrolithotomy (large stones), percutaneous nephrolithotomy, intracorporeal lithotripsy, and, in cases of recently formed stones, extracorporeal shock wave lithotripsy. These procedures carry a risk of progressive renal impairment.

[0008] The pharmacological approach is based on the oral administration of thiol-based agents (such as penicillamine and tiopronin), which can replace the redox balance between cystine (insoluble) and cysteine ​​(soluble) by forming a soluble complex with cysteine. Although these agents are quite effective, they have a variety of side effects that lead to treatment interruption and disease recurrence (HalperinEC et al., "The use of D-penicillamine in cystinuria: efficacy and untoward reactions", Yale J Biol Med., 1981, vol. 54 (6), pp. 439-46).

[0009] Therefore, there remains a need for simple and inexpensive methods to identify the onset of cystine stones in cystinuric patients and for effective and non-toxic treatments to prevent or delay cystine stone formation. SUMMARY OF THE INVENTION

[0011] The present inventors have developed a new method for diagnosing cystine stones based on the detection of S-methyl-L-ergothioneine (S-met-L-Erg) in a patient's urine sample.

[0012] As shown in the following examples, the inventors were surprised to find that the level of the amino acid derivative S-met-L-ergothioneine in urine can determine the presence of kidney cystine stones with strong statistical power. This is very unexpected, because S-met-L-ergothioneine is a metabolite without any known connection with human disease, which has never been detected in the sample of cystinuria patients. Therefore, the inventors have developed a method that allows accurate diagnosis of cystine stones in cystinuria patients by simply analyzing the single metabolite in the sample that is easy to obtain.

[0013] Prior to the present invention, the presence of cystine stones in cystinuric patients could only be determined by complex imaging techniques. Therefore, clinical management of cystinuric patients included increased fluid intake and urine alkalinization until the level of urine cystine or renal pain indicated the possible onset of stone attack. Only then, the presence of cystine stones can be determined by imaging techniques such as CT scans or ultrasound. These techniques require expensive equipment and cannot even distinguish cystine from other stone chemicals.

[0014] The simplicity and effectiveness of the methods provided herein allow routine testing for urolithiasis in cystinuric patients. This significant improvement will help detect cystine stones at their onset before they produce any symptoms in patients, thereby reducing patient suffering and allowing treatment optimization.

[0015] Thus, in a first aspect, the present invention provides S-methyl-L-ergothioneine for use in diagnosis and / or prognosis.

[0016] In a second aspect, the present invention provides a method for diagnosing and / or prognosing renal disease, the method comprising the step of determining the amount of S-methyl-L-ergothioneine in an isolated test sample of a subject.

[0017] As described in the examples below, in the cystinuria animal model, the amount of S-methyl-L-ergothioneine in urine is lower than that in control animals (wild type-WT). Therefore, S-methyl-L-ergothioneine is a useful tool for determining or recommending the initiation of therapeutic intervention to avoid, prevent or reduce urolithiasis.

[0018] In a third aspect, the present invention provides a method for deciding or recommending whether to initiate therapeutic intervention for a subject suspected of having kidney disease, wherein the method comprises the following steps: (a) determining the amount of S-methyl-L-ergothioneine in an isolated test sample of the subject; and

[0019] (b1) deciding or recommending to initiate therapeutic intervention if the amount of S-methyl-L-ergothioneine is within the reference value range for subjects with renal disease; or,

[0020] (b2) comparing the amount of S-methyl-L-ergothioneine in the isolated test sample of the subject with a reference value, wherein the reference value is a reference value for a subject not suffering from kidney disease; wherein, if the amount of S-methyl-L-ergothioneine measured in step (a) is lower than the reference value, it is indicated that the subject must start therapeutic intervention.

[0021] In a fourth aspect, the present invention provides a method for determining the efficacy of a therapeutic intervention in a subject who has been diagnosed with kidney disease, the method comprising the following steps: (a) measuring the amount of S-methyl-L-ergothioneine in an isolated test sample of the subject before the therapeutic intervention; (b) once the therapeutic intervention begins, measuring the amount of S-methyl-L-ergothioneine in an isolated biological sample of the subject; and (c) comparing the amounts measured in steps (a) and (b), such that if the amount of S-methyl-L-ergothioneine measured in step (b) is higher than the amount of S-methyl-L-ergothioneine measured in step (a), then indicating that the medical regimen Can effectively treat kidney disease; or, the method comprises the following steps: (i) once therapeutic intervention begins, measuring the amount of S-methyl-L-ergothioneine in a test sample isolated from the subject; and (ii) comparing the amount measured in step (i) with a reference value of S-methyl-L-ergothioneine, the reference value being a reference value for a subject not suffering from kidney disease, or the reference value being the amount of S-methyl-L-ergothioneine in a test sample isolated from a subject suffering from kidney disease at a previous test moment, wherein, if the amount of S-methyl-L-ergothioneine measured in step (i) is not less than the reference value, it indicates that the medical regimen can effectively treat kidney disease.

[0022] In a fifth aspect, the present invention provides use of a device for determining the amount of S-methyl-L-ergothioneine in a method as defined above.

[0023] In a sixth aspect, the present invention provides use of S-methyl-L-ergothioneine as a marker for diagnosis and / or prognosis of renal disease in an isolated test sample of a subject.

[0024] In another aspect, the present invention provides a ratio of S-methyl-L-ergothioneine / L-ergothioneine for use in diagnosis and / or prognosis.

[0025] The present inventors have also developed a new treatment for cystine stones.

[0026] Surprisingly, as shown in the following examples, the present inventors have discovered that administration of ergothioneine (Erg) prevents or delays the appearance of kidney stones in a mouse model of cystinuria.

[0027] Current pharmacological treatments for cystine stones are based on thiol-based agents that dissolve cystine stones by breaking disulfide bonds, thereby forming mixed cysteine ​​disulfide compounds that are more soluble in urine. These known drugs exhibit varying degrees of efficacy and strong secondary effects, which limit their use to short periods of time (Halperin EC et al., supra). As a result, cystinuric patients present with a high rate of disease recurrence, which can lead to infection and renal failure.

[0028] Unexpectedly, the inventors found that the use of ergothioneine not only prevents and delays cystine stone formation, but also does not produce any side effects in cystinuric mice. This will allow long-term treatment of cystinuric patients, thereby greatly reducing stone disease and recurrence. Without wishing to be bound by theory, the different mechanisms of action of the ergothioneine found by the inventors may be the reason for its extraordinary properties. Contrary to the thiol-based reagents currently used, ergothioneine does not directly act on cystine stones. However, it stimulates the synthesis of glutathione, and increases the intracellular level of cysteine, methionine, g-glutamyl-cysteine ​​in renal cells and the intracellular ratio of cysteine / cystine, and reduces the redox potential of urine.

[0029] The significant advantages shown by the novel therapy provided herein are clear indications for the prevention or even treatment of cystine stones in human patients. In fact, as shown in the following examples, ergothioneine reduces the number of mice that form stones by 50%; and, relative to untreated mice, the remaining 50% of stones formed are delayed by 1 month, and in addition, the growth rate of the stones formed is lower.

[0030] In view of the above, the novel treatments for cystine stones provided herein constitute a tremendous advance in the field of medicine, particularly for the treatment of this inherited disorder.

[0031] Therefore, in a seventh aspect, the present invention provides ergothioneine for use in treating and / or preventing kidney stones or aminoaciduria.

[0032] This aspect can also be exactly expressed as the purposes of thioneine in the preparation of a medicine for treating and / or preventing a disease selected from kidney stone and aminoaciduria. This aspect can also be exactly expressed as a method for treating and / or preventing a disease selected from kidney stone and aminoaciduria, and the method comprises administering the thioneine of a therapeutically effective amount to a subject in need.

[0033] The mechanism of action of ergothioneine makes it particularly suitable for supplementing currently used therapies with cystine solubilizing agents. Their combined use will allow the stones formed to be removed simultaneously, and prevent the formation of new stones. In addition, the use of ergothioneine may allow the toxicity of current treatments to be reduced.

[0034] Therefore, in an eighth aspect, the present invention provides ergothioneine for use in combination therapy with a compound selected from an additional cystine solubilizer, L-cystine dimethyl ester, L-cystine methyl ester, L-cystine diamide, lipoic acid and a combination thereof, for treating and / or preventing kidney stones or aminoaciduria.

[0035] This aspect can also be exactly expressed as the purposes of ergothioneine in the preparation for the treatment of a compound selected from additional cystine solubilizing agent, L-cystine dimethyl ester, L-cystine methyl ester, L-cystine diamide, thioctic acid and combinations thereof in a medicine for treating and / or preventing a disease selected from kidney stones and aminoaciduria. This aspect can also be exactly expressed as a method for treating and / or preventing a disease selected from kidney stones and aminoaciduria, the method comprising administering a therapeutically effective amount of ergothioneine to a subject in need thereof and combining with a compound selected from additional cystine solubilizing agent, L-cystine dimethyl ester, L-cystine methyl ester, L-cystine diamide, thioctic acid and combinations thereof.

[0036] BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 .Determination of L-Erg and S-Met-L-Erg in urine of 6-month-old male mice. 6-month-old wt and Slc7a9 - / - Urinary L-Erg and S-Met-L-Erg concentrations in (KO) male mice. Each point represents a sample and the bars represent the mean ± SEM. The Mann-Whitney probability test values ​​are shown at the top of each graph.

[0038] Figure 2 . Differences in L-Erg and S-Met-L-Erg concentrations in urine of male mice of different ages. 3-month-old and 6-month-old wt and Slc7a9 - / - (KO) Urinary L-Erg and S-Met-L-Erg concentrations in male mice. Bars represent mean ± SEM. Mann-Whitney probability test values ​​are expressed as **, P ≤ 0.01 for 3 months vs. 6 months, ***, P ≤ 0.001, and +++, P ≤ 0.001 for wt vs. KO.

[0039] Figure 3 Sex-related differences in urinary L-Erg and S-Met-L-Erg concentrations in 6-month-old wt and Slc7a9 mice - / - L-Erg and S-Met-L-Erg concentrations in urine of (KO) mice. Bars represent mean ± SEM. Mann-Whitney probability test values ​​are represented as *, P ≤ 0.05, **, P ≤ 0.01, ***, P ≤ 0.001, ****, P ≤ 0.0001 vs. male mice, and +, P ≤ 0.05, +++, P ≤ 0.001 vs. wt mice. "M" represents male, and "F" represents female.

[0040] Figure 4Urinary concentrations of L-Erg and S-Met-L-Erg in cystinuric mice of stone formers and non-formers. - / - ) were associated with the presence (SF) or absence (NSF) of cystine stones by sex. Stone former (SF) mice were subdivided into: ESF, stones detected before 3 months of age, and LSF, stones detected after 3 months of age at the time of stone detection. Bars represent mean ± SEM. Mann-Whitney probability test values ​​are expressed as P ≤ 0.1, *, P ≤ 0.05, **, P ≤ 0.01, ***, P ≤ 0.001, vs. non-stone forming mice, and +, P ≤ 0.05, ++P ≤ 0.05, +++, P ≤ 0.001 vs. male mice. "M" indicates male, and "F" indicates female.

[0041] Figure 5 . Urinary S-Met-L-Erg / L-Erg ratio in cystinuric mice. A. Slc7a9 in stone formers (SF) and non-stone formers (NSF) - / - Urinary S-Met-L-Erg / L-Erg ratio in mice. Bars represent mean ± SEM. Mann-Whitney probability test values ​​are represented as *, P ≤ 0.05, ***, P ≤ 0.001, ****, P ≤ 0.0001 vs. non-stone forming mice. B. Receiver-operator characteristic curves showing the performance of the urinary S-Met-L-Erg / L-Erg ratio in distinguishing SF from NSF. AUC, area under the curve. The y-axis represents the true positive fraction, and the x-axis represents the false positive fraction.

[0042] Figure 6(Related to Example 2). Metabolic changes caused by L-Erg treatment. Water intake normalized by mouse surface (A), pH (B) and redox potential (C) before (initial, left bar, "B") and after (final, right bar, "A") treatment with different concentrations of L-Erg supplemented in drinking water. Each point represents one mouse. Wilcoxon test results. pH and redox potential could not be determined in all treated mice because urine volume was below the lower limit of pH and redox electrodes. Urinary L-Erg concentration (D) and S-Met-L-Erg (E) concentrations on a semi-logarithmic scale for visualization purposes before (B) (initial, left bar) and after (A) (final, right bar) treatment with different concentrations of L-Erg supplemented in drinking water. Each point represents a mouse and the bars represent the mean ± SEM. In all panels, ns, non-significant; *p<0.05 using Wilcoxon signed rank test. The initial values ​​before treatment correspond to the left bar in each graph (AE) and / or each L-Erg test dose. The final values ​​after treatment correspond to the right bar in each graph (AE) and / or each L-Erg test dose. The x-axis represents L-Erg (mg / L) and the y-axis represents water intake / body weight. 2 / 3 Ratio (ml / kg 2 / 3 )(A); pH(B); ORP(mV)(C); [L-ergothioneine in urine(μM)(D); [S-methyl-L-ergothioneine] in urine(μM)(E).

[0043] Figure 7 (Related to Example 2). Stone growth rate in L-Erg treated lithiasis mice. Male and female mice were treated (ERG) or not treated (C) with 60 mg / L L-Erg in drinking water for 3 months. The y axis represents the stone growth rate (mg / day). The bars represent the mean ± SEM of the stone growth rate determined monthly by X-ray imaging of 13-15 mice. Each point represents the cystine stone growth rate determined for each mouse.

[0044] Figure 8(Related to Example 2). Effect of chronic (6 months) L-Erg treatment on cystine stone onset and metabolic parameters. (A) Effect on cystine stone onset. The percentage of mice with stones during the 6-month treatment and necropsy period for L-Erg-treated (ERG) and untreated mice (control) is shown. The y-axis represents the % of cystine stones, and the x-axis represents the treatment time, expressed in months. (B) Effect on stone growth rate. The stone growth rate for each mouse on those stones with more than 2 data points was calculated by a linear regression model. The y-axis represents the stone growth rate (mg / day). The bars show the mean ± SEM of untreated mice (C, n=7) and L-Erg-treated mice (ERG, n=3). The results of the statistical analysis are shown at the top. (C) Effect on urine pH. The urine pH of L-Erg-treated (ERG) and untreated (C) mice was monitored at the end of the treatment period. (D) Effect on urine redox potential. Urinary ORP of L-Erg treated (ERG) and untreated (control) mice was monitored at the end of the treatment period. The results of the statistical analysis are shown at the top. In (C) and (D), the large black dots represent the mean and the small black dots are located above and below the boxes for outliers.

[0045] Fig. 9 (Related to Example 2). L-Erg increases intracellular renal concentrations of transsulfuration pathway components. The figure shows the intracellular content of those metabolites of the transsulfuration pathway in the kidneys of chronically treated and untreated mice. The y axis represents nmol / mg protein. Glutathione (GSH) in (A); oxidized glutathione (GssG) in (B); GSH / GssG ratio in (C); cysteine ​​(Cys) in (D); cystine (CssC) in (E); Cys / CssC ratio in (F); S-adenosylhomocysteine ​​(SAH) in (G); S-adenosylmethionine (SAM) in (H); SAM / SAH ratio in (I); methionine (Met) in (J); γ-glutamylcysteine ​​(γGluCys) in (K); and cystathionine in (L). Each point represents a mouse and the bars represent the mean ± SEM. In all panels; *p<0.05, **, P≤0.01, ***, P≤0.001, ****, P≤0.0001 using Wilcoxon signed-rank test.

[0046] Fig.10 (Related to Example 3). Two different mouse models of cystinuria (Slc7a9 - / - Slc3a1 D140G Urinary ORP (mV) in cystinuric mice from the type I cystinuria mouse model 129S2 / SvPasCrl(Slc3a1 E383K) Preliminary data. Wilcoxon signed-rank test, *p<0.05, **, P≤0.01. DETAILED DESCRIPTION OF THE INVENTION

[0048] Unless otherwise specified, all terms used in this application should be understood with ordinary meanings known in the art. Other more specific definitions of certain terms used in this application are described below, and unless otherwise explicitly stated, the definitions provide a broader definition, it is intended to be uniformly applied throughout the specification and claims.

[0049] As used herein, the indefinite articles "a" and "an" are synonymous with "at least one" or "one or more." Definite articles such as "the" as used herein also include plural forms of the noun unless otherwise stated.

[0050] As used herein, "diagnosis" is understood to mean becoming aware of a particular medical condition complication or risk in a subject; determining the nature of a disease or condition; or distinguishing one disease or condition from another. It refers both to the process of attempting to determine or identify a possible disease or condition and to the opinion obtained through that process. In the sense of a diagnostic procedure, diagnosis can be considered an attempt to classify an individual's condition into separate and distinct categories that allow medical decisions about treatment and prognosis to be made. Subsequently, diagnostic opinions are typically described in terms of disease or other conditions. However, diagnosis can take many forms. It may be a matter of detecting the presence and naming of a disease, lesion, dysfunction, or disability. It may be an exercise in attributing categories to management or prognosis. It may indicate a degree of abnormality on a continuum or a type of abnormality in a classification.

[0051] As used herein, "prognosis" refers to the prediction of the likely development and outcome of a disease. In the present case, in a specific embodiment, prognosis refers to the distinction between patients who will develop stone disease and those who will not.

[0052] In the present invention, the term "reference value" mentioned in the method of the present invention should be understood as the predetermined value of S-met-L-erg obtained by the amount of the molecular marker in the sample or sample group. The sample is taken from a subject or a subject group, wherein the presence, absence, stage, histological subtype or grade of the disease or the course of disease has been appropriately performed. This value is used as a threshold value to distinguish between subjects with the condition to be analyzed and subjects without such conditions. The reference value can also be used to determine whether a subject must start a medical regimen and how effective the regimen is. One or more subjects from which reference values ​​are obtained may include subjects in which the condition is not present, subjects in which the condition is present, or both. Using general knowledge, those skilled in the art can select subjects or subject groups that are more suitable for obtaining reference values ​​for each method of the present invention. The method for obtaining reference values ​​from the selected subject group is well known in the prior art (Burtis CA et al., 2008, Chapter 14, section "Statistical Treatment of Reference Values"). In certain cases, a "reference value" is a cutoff value defined by conventional ROC analysis (receiver-operator characteristic analysis). Those skilled in the art will appreciate that the optimal cut-off value will be defined according to the specific application of the diagnostic or prognostic method: the purpose for diagnosis or prognosis, the target population, the balance between specificity and sensitivity, etc. The term "reference value" as used herein can be an absolute value; a relative value; a value with an upper or lower limit; a range of values; an average value; a median value; a mean value or a value compared to a specific control or baseline value.

[0053] The level of a biomarker (in the present invention, any one of L-Erg or S-met-L-erg) is considered to be above its reference value when the level of the biomarker is at least 1.5%, at least 2%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150% or more above the reference value. Likewise, in the context of the present invention, when the level of a biomarker in a sample is below a reference value, the level of the biomarker is reduced. The level of a biomarker is considered to be below its reference value when the level of the biomarker is at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150% or more below the reference value.

[0054] As used herein, "treatment" refers to encompassing complete or partial relief or restoration of a patient's health. "Therapeutic intervention" refers to administering a treatment suitable for a particular disease. In a specific embodiment, therapeutic intervention includes administering ergothioneine.

[0055] The term "cystine solubilizer" refers to compounds that have the ability to increase the solubility of cystine in the urinary tract. In particular, these compounds are thiol-based agents, such as penicillamine, which disrupt the disulfide bonds of cystine and form mixed cysteine ​​disulfide compounds. "Additional cystine solubilizer" is intended to include any cystine solubilizer other than ergothioneine.

[0056] The expression "pharmaceutical composition" encompasses two compositions intended for humans and for non-human animals (i.e., veterinary compositions). In particular, ergothioneine can also be used to treat livestock, such as cats and dogs, which are known to develop cystine stones. The pharmaceutical composition of the present invention contains a therapeutically effective amount of ergothioneine. As used herein, the expression "therapeutically effective amount" refers to the amount of the compound that is sufficient to prevent the development of one or more symptoms of the disease or illness being addressed or to alleviate one or more symptoms of the disease or illness being addressed to a certain extent when applied. The specific dosage of the reagent used according to the present invention will certainly be determined by the specific circumstances surrounding the case, including route of administration, specific illness being treated, and similar considerations.

[0057] The expression "pharmaceutically acceptable carrier or excipient" refers to a pharmaceutically acceptable material, composition or vehicle. Each component must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the pharmaceutical composition. It must also be suitable for contact with tissues or organs of humans and non-human animals without excessive toxicity, irritation, allergic response, immunogenicity or other problems or complications, with a reasonable benefit / risk ratio.

[0058] Examples of suitable pharmaceutically acceptable excipients are solvents, dispersion media, diluents or other liquid vehicles, dispersion or suspension aids, surfactants, isotonicity agents, thickeners or emulsifiers, preservatives, solid binders, lubricants, etc. Unless any conventional excipient medium is incompatible with the substance or its derivatives, for example by producing any undesirable biological effect or interacting in a deleterious manner with any other component of the pharmaceutical composition, its use is intended to be within the scope of the present invention.

[0059] The relative amounts of ergothioneine, pharmaceutically acceptable excipients and / or any additional ingredients in the pharmaceutical compositions of the present invention will vary depending on the identity, size and / or condition of the subject being treated and further depending on the route of administration of the composition.

[0060] Pharmaceutically acceptable excipients for preparing pharmaceutical compositions include, but are not limited to, inert diluents, dispersants and / or granulating agents, surfactants and / or emulsifiers, disintegrants, binders, preservatives, buffers, lubricants and / or oils. Excipients such as coloring agents, coating agents, sweeteners and flavoring agents may be present in the composition according to the formulator's judgment.

[0061] The pharmaceutical compositions containing ergothioneine may be in any dosage form, such as solid or liquid, and may be administered by any suitable route, such as oral, parenteral, topical, intranasal or sublingual, for which they will include the pharmaceutically acceptable excipients necessary for formulation of the desired dosage form.

[0062] It will be clear to those skilled in the art that the compositions can be prepared using state of the art excipients and applying common pharmaceutical techniques.

[0063] The dosage form may be a solid pharmaceutical composition such as tablets or coated tablets, powders, fine granules, granules, capsules (such as hard or soft gelatin capsules), lozenges (caplets), boluses, and chewable preparations containing ergothioneine.

[0064] Alternatively, the pharmaceutical composition can be a semisolid or liquid dosage form, such as a gel (e.g., a hydrogel), a cream, an ointment, a lotion, a water-in-oil or oil-in-water emulsion, a suspension, an aerosol and a liquid preparation (e.g., a solution), an elixir, a syrup (including a dry syrup).

[0065] If the pharmaceutical composition containing ergothioneine of the present invention is in the form of a solid preparation for oral administration (such as tablets) or a liquid preparation for oral or nasal administration, it can be administered to a patient once a day or several times a day in divided doses.

[0066] In the preparation of the composition containing ergothioneine, a variety of currently used additives can be used, such as one or more fillers, thickeners, gelling agents, adhesives, disintegrants, surfactants, lubricants, coating agents, sustained release agents, diluents and / or one or more excipients. In addition to the above, if necessary, the reagent of the present invention can also include other additives, such as solubilizers, buffers, preservatives, isotonic agents, emulsifiers, suspending agents, dispersants, hardeners, absorbents, adhesives, elastic agents, adsorbents, spices, colorants, flavoring agents, antioxidants, wetting agents, opacifiers, brighteners, tackifiers, oils, tableting aids and / or antistatic agents.

[0067] More specifically, examples of such additives include one or more excipients such as lactose, corn starch, mannitol, D-sorbitol, crystalline cellulose, erythritol and sucrose; binders such as hydroxypropyl cellulose (HPC-L), hydroxypropyl methylcellulose, polyvinyl pyrrolidone, methyl cellulose and gelling starch; disintegrants such as carboxymethyl cellulose calcium, cross-linked carboxymethyl cellulose sodium and cross-linked polyvinyl pyrrolidone (crospovidone); lubricants such as magnesium stearate and talc; flavors such as seasonings or aromatic oils such as apple flavor, honey flavor, 1-menthol, vanillin, lemon oil, cinnamon oil, mint oil or peppermint oil; and / or adsorbents such as synthetic aluminum silicate and light anhydrous silicic acid.

[0068] Furthermore, a coated pharmaceutical preparation can also be prepared by using a currently used coating agent such as hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose or polyvinylpyrrolidone.

[0069] If necessary, sweeteners such as lozenges, syrups and chewing preparations can also be used. Specific examples of such sweeteners are mannitol, glucose, maltose, starch syrup, malt extract paste, maltitol, sorbitol, sucrose, unrefined sugar, fructose, lactose, honey, xylitol, hydrangea tea, saccharin, aspartame, cyclamates, Aspartame and other maltooligosaccharides, as well as oligosaccharides such as maltosylsucrose, reduced isomaltose and raffinose, acesulfame potassium or any kind of sugar alcohol or mixtures thereof such as sorbitol, mannitol and / or xylitol.

[0070] As the solubilizer, any known solubilizer suitable for use in the medical field can be used, such as polyethylene glycol, polyoxyethylene-polyoxypropylene copolymers (e.g., poloxamer 188), tetraethylene glycol, arginine, lysine, castor oil, propylene glycol, glycerol acetone acetal, polysorbate, glycerol, polyvinyl pyrrolidone, lecithin, cholesterol, 12-hydroxystearic acid-PEG660-ester, propylene glycol monostearate, polyoxy-40-hydrogenated castor oil, polyoxyl-10-oleyl-ether, polyoxyl-20-cetyl-stearyl ether and polyoxyl-40-stearate or a mixture thereof.

[0071] Any preservative known for use in the pharmaceutical field may be used, for example ethanol, benzoic acid and its sodium or potassium salts, sorbic acid and its sodium or potassium salts, chlorobutanol, benzyl alcohol, phenylethanol, methylparaben, ethylparaben, propylparaben or butylparaben, phenol, m-cresol, p-chloro-m-cresol, those selected from the group consisting of PHB esters, for example a mixture of PHB-methyl ester and PHB-propyl ester, quaternary ammonium compounds such as benzalkonium chloride, thimerosal, phenylmercuric salts (e.g. nitrates, borates).

[0072] The buffer system used to obtain the desired pH value can be, for example, glycine, a mixture of glycine and HCl, a mixture of glycine and sodium hydroxide solution, and their sodium and potassium salts, a mixture of potassium hydrogen phthalate and hydrochloric acid, a mixture of potassium hydrogen phthalate and sodium hydroxide solution or a mixture of glutamic acid and glutamate.

[0073] Suitable gelling agents are, for example, cellulose and its derivatives, such as methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinyl pyrrolidone, polyacrylates, poloxamers, tragacanth, carrageenan, starch and its derivatives or any other gelling agent used in pharmaceutical technology.

[0074] Viscosity enhancers which may be mentioned are, for example, the abovementioned gelling agents in small amounts, glycerol, propylene glycol, polyethylene glycol or polyols such as sorbitol and other sugar alcohols.

[0075] The emulsifier used may include, in addition to the emulsifiers known from the prior art, polyoxyethylene derivatives of castor oil or polyoxyethylene alkyl ethers.

[0076] Suitable synthetic or natural colorants known in the pharmaceutical art may be used, for example indigo carmine.

[0077] Suitable oily components that may be present are any oily substances known in the prior art for the preparation of medicaments, for example vegetable oils, in particular cottonseed oil, groundnut oil, peanut oil, corn oil, rapeseed oil, sesame oil and soybean oil, or medium-chain triglycerides, for example fractionated coconut oil, or isopropyl myristate, palmitate or mineral oil or ethyl oleate.

[0078] The antioxidant used may be any antioxidant known in the art, such as alpha-tocopherol, butylhydroxytoluene (BHT) or butylhydroxyanisole (BHA).

[0079] Depending on the dosage form, pharmaceutical compositions containing these additives can be prepared according to any method known in the art. Of course, other additives not explicitly discussed may be used in the formulations used according to the invention.

[0080] As described above, the inventors first discovered that S-met-L-erg is associated with medical diseases or conditions. Therefore, the present invention provides S-methyl-L-ergothioneine for diagnosis and / or prognosis.

[0081] S-Methyl-L-ergothioneine is the known methyl derivative form of ergothioneine.

[0082] Ergothioneine has the IUPAC name [1-carboxy-2-(2-sulfanylidene-1,3-dihydroimidazol-4-yl)ethyl]-trimethylammonium azine, CAS number 497-30-3, and formula (I):

[0083]

[0084] S-Methyl-L-ergothioneine has the IUPAC name (2-{S})-3-(2-methylthio-1-{H}-imidazol-5-yl)-2-(trimethylazinium)propionate and formula (II):

[0085]

[0086] In a specific embodiment optionally in combination with any embodiment provided above or below, S-methyl-L-ergothioneine is used for diagnosis and / or prognosis of nephropathy. In a more specific embodiment, nephropathy is kidney stones or aminoaciduria. In another specific embodiment, kidney stones are cystine stones. In a more specific embodiment, the aminoaciduria is cystinuria.

[0087] As described above, the second aspect of the present invention provides a method for diagnosing or prognosing renal disease, the method comprising the step of determining the amount of S-methyl-L-ergothioneine in an isolated test sample of a subject.

[0088] In a specific embodiment of the above method, optionally in combination with any embodiment provided above or below, the method further comprises a step of comparing the amount of S-methyl-L-ergothioneine of the subject with a reference value, wherein if the amount determined in the subject is within the reference value (reference value) range for subjects with kidney disease, it indicates that the subject is suspected of having the kidney disease; and wherein if the amount is within the range of values ​​for healthy subjects or subjects not suffering from any kidney disease (particularly not suffering from kidney stones or aminoaciduria), it indicates that the subject is not suspected of having the kidney disease.

[0089] In a specific embodiment of the above method optionally combined with any embodiment provided above or below, the method further comprises a step of comparing the amount of S-methyl-L-ergothioneine of the subject with a reference value, wherein if the amount measured in the subject is different from the reference value, the reference value is a reference value for a healthy subject or a subject not suffering from any nephropathy, then the subject is indicated to be suspected of having nephropathy. In a specific embodiment, if the amount measured in the subject is lower than the reference value, the reference value is a reference value for a subject not suffering from nephropathy, particularly not suffering from kidney stones or aminoaciduria, then the subject is indicated to be suspected of having nephropathy. In another more specific embodiment, if the amount measured in the subject is lower than the reference value, then a poor prognosis is indicated.

[0090] As shown in the examples below, the inventors found that the ratio of the amount of S-methyl-L-ergothioneine and L-ergothioneine in urine samples provided better statistical results for distinguishing between lithiasis mice and non-lithiasis mice ( Figure 5 B) In fact, the S-methyl-L-ergothioneine / L-ergothioneine ratio allowed the classification of mice with 100% specificity and sensitivity using two different analytical methods.

[0091] Therefore, in a specific embodiment of the above method optionally combined with any embodiment provided above or below, the method further comprises the step of measuring the amount of ergothioneine in the test sample of the separation of the subject. In an even more specific embodiment, the method further comprises the step of measuring the amount of ergothioneine in the test sample of the separation of the subject and calculating the ratio of the amount of S-methyl-L-ergothioneine to L-ergothioneine.

[0092] In a specific embodiment of the above method, optionally in combination with any embodiment provided above or below, the method further comprises the following steps: determining the amount of L-ergothioneine in the isolated test sample of the subject, calculating the ratio of the amount of S-methyl-L-ergothioneine to L-ergothioneine, and comparing the ratio with a reference value, wherein if the ratio determined in the subject is within the range of the reference value (reference value) for subjects with kidney disease, it indicates that the subject is suspected of having the kidney disease; and wherein if the ratio is within the range of values ​​for healthy subjects or subjects not suffering from any kidney disease (particularly not suffering from kidney stones or aminoaciduria), it indicates that the subject is not suspected of having the kidney disease.

[0093] In a specific embodiment of the above method optionally combined with any embodiment provided above or below, the method further comprises the following steps: determining the amount of L-ergothioneine in the test sample separated from the subject, calculating the ratio of the amount of S-methyl-L-ergothioneine to L-ergothioneine, and comparing the ratio with a reference value, wherein if the ratio determined in the subject is different from the reference value, the reference value is a reference value for a healthy subject or a subject not suffering from any kidney disease, particularly a subject not suffering from kidney stones or amino aciduria, then the subject is indicated to be suspected of having kidney disease. In a more specific embodiment, if the ratio determined in the subject is lower than the reference value, then the subject is indicated to be suspected of having kidney disease.

[0094] S-methyl-L-ergothioneine and L-ergothioneine levels can be measured according to the routine techniques in diagnostics field. Those skilled in the art can adjust the parameters of technology to obtain optimal results. Therefore, in a specific embodiment of the above method, the amount of S-methyl-L-ergothioneine and / or L-ergothioneine is measured by mass spectrum, high performance liquid chromatography (HPLC), derivatization, chemical detection and combination thereof.

[0095] As mentioned above, another aspect of the present invention provides the use of a device for determining the amount of S-methyl-L-ergothioneine in a method as defined above.

[0096] In certain embodiments, optionally in combination with any of the embodiments provided above or below, the device forms part of a kit.

[0097] As used herein, the term "kit" refers to a product containing the different reagents (or reagent sets) required for carrying out the method of the present invention, which are packaged to allow their transportation and storage. Materials suitable for packaging the components of the kit include crystals, plastics (e.g., polyethylene, polypropylene, polycarbonate), bottles, vials, paper or envelopes.

[0098] In a particular embodiment of the invention, the device for determining the amount of S-methyl-L-ergothioneine comprises isotope-labeled S-methyl-L-ergothioneine and / or L-ergothioneine, more particularly deuterated S-methyl-L-ergothioneine and / or L-ergothioneine, and the method is carried out by adding labeled S-methyl-L-ergothioneine and / or labeled L-ergothioneine to the test sample as an added compound or mixture. In a more specific embodiment, the device comprises a mixture of isotope-labeled S-methyl-L-ergothioneine and isotope-labeled L-ergothioneine.

[0099] In this specific embodiment using isotopically labeled S-methyl-L-ergothioneine and / or L-ergothioneine, a device comprising non-isotopically labeled S-methyl-L-ergothioneine and / or L-ergothioneine is also included for use as a positive control means in the method.

[0100] Therefore, the specific test kit for implementing the inventive method comprises or is composed of: the first vial with a composition comprising isotope-labeled S-methyl-L-ergothioneine and / or L-ergothioneine; and the second vial with a composition comprising S-methyl-L-ergothioneine and / or L-ergothioneine. In these test kits, the first vial includes a device for adding the separated sample of the test to the standard curve for quality control (QC) test. The second vial includes a device for preparing a standard curve.

[0101] In addition, the test kit of the present invention may include the instructions for use simultaneously, sequentially or respectively using different devices to measure the amount of S-methyl-L-ergothioneine and / or L-ergothioneine in the test kit. The instructions may be in the form of printed material or may store the form of an electronic carrier of the instructions that are easy to read or understand, such as an electronic storage medium (such as a disk, a magnetic tape) or an optical medium (such as a CD-ROM, a DVD) or an audio material. Additionally or alternatively, the medium may include the Internet address providing the instructions.

[0102] As mentioned above, the present invention provides S-methyl-L-ergothioneine as the purposes of the marker for diagnosing and / or prognosing nephropathy in the test sample of the separation of the experimenter on the other hand.In a specific embodiment, S-methyl-L-ergothioneine is used as the marker for diagnosing and / or prognosing nephropathy in the test sample of the separation of the experimenter together with L-ergothioneine.In a more specific embodiment, the ratio of the amount of S-methyl-L-ergothioneine and L-ergothioneine is used as the marker for diagnosing and / or prognosing nephropathy in the test sample of the separation of the experimenter.

[0103] In a specific embodiment of the above defined methods and uses optionally in combination with any embodiment provided above or below, the separated test sample is selected from serum, plasma, saliva, pleural fluid, cerebrospinal fluid (CSF), blood, amniotic fluid, urine, feces, mucus, cell extracts and pus. In a more specific embodiment optionally in combination with any embodiment provided above or below, the separated test sample is a urine sample.

[0104] In a specific embodiment of the above defined methods and uses, optionally in combination with any embodiment provided above or below, the subject suffers from aminoaciduria. In a more specific embodiment, the aminoaciduria is cystinuria. As shown in the following examples, the methods of the present invention are particularly useful for diagnosing cystine stones in subjects suffering from cystinuria.

[0105] It is known that various mammals form cystine stones in the kidney due to abnormal accumulation of cystine in urine. The method of the present invention is applicable to all of these methods. Therefore, in another specific embodiment of the method and use defined above, optionally in combination with any embodiment provided above or below, the subject is a mammal. In a more specific embodiment, the mammal is a livestock mammal. In another specific embodiment, optionally in combination with any embodiment provided above or below, the mammal is a human.

[0106] In the specific embodiment of S-methyl-L-ergothioneine for the purposes disclosed above, the methods and purposes defined above, optionally in combination with any embodiment provided above or below, the kidney disease is kidney stones or aminoaciduria. In a more specific embodiment, kidney stones are cystine stones. In another specific embodiment, aminoaciduria is cystinuria.

[0107] Thus, in a specific embodiment, optionally in combination with any of the embodiments provided above or below, the method is used to diagnose cystine stones. More particularly, the method is used to diagnose cystine stones in a subject suffering from cystinuria. In another specific embodiment, the method is used for the prognosis of cystinuria. The method of the present invention can be used to determine the presence of cystine stones and can also be used to predict the occurrence of cystine stones in a subject suffering from cystinuria.

[0108] As mentioned above, it is particularly important to diagnose urolithiasis as quickly as possible to provide adequate treatment and avoid complications resulting from large kidney stones (ie, obstruction, infection, and renal failure). The method of the present invention allows such timely diagnosis.

[0109] All methods and uses provided herein can be performed by determining the amount of S-methyl-L-ergothioneine, or the amounts of S-methyl-L-ergothioneine and L-ergothioneine in a separated test sample and calculating the ratio of S-methyl-L-ergothioneine / L-ergothioneine.

[0110] Therefore, as described above, in another aspect, the present invention provides the ratio of S-methyl-L-ergothioneine / L-ergothioneine for diagnosis and / or prognosis.All the above provided embodiments are also intended to apply to this additional aspect.

[0111] The inventors also realized that the urine oxidation reduction potential or redox state (ORP) of the cystinuric mouse model that does not form cystine stones is lower than the urine ORP in stone-forming mice. Therefore, this parameter is also proposed for in vitro differential diagnosis or prognosis of cystinuric animals (including humans).

[0112] Redox potential (also known as oxidation / reduction potential, ORP) is a measure of the tendency of a chemical species (i.e., a separated sample; urine) to gain electrons from an electrode or to lose electrons from an electrode, thereby being reduced or oxidized, respectively. Redox potential is measured in volts (V) or millivolts (mV). Each substance has its own intrinsic redox potential; for example, the more positive the reduction potential (reduction potential is more often used due to the general formalism in electrochemistry), the greater the substance's affinity for electrons and tendency to be reduced.

[0113] In more particular embodiments of any of the methods disclosed above for diagnosis or prognosis of kidney disease, particularly kidney stones or aminoaciduria, more particularly cystine stones and cystinuria provided herein, the method further comprises:

[0114] (a) determining the oxidation-reduction potential (ORP) of a sample isolated from a subject, in particular a urine sample;

[0115] (b) comparing the ORP of (a) with a reference value; and

[0116] (c) if (c1) the ORP is within a reference value range for non-stone-forming subjects, or if (c2) the ORP is below a reference value obtained from a subject previously classified as stone-forming, the subject is diagnosed as a non-stone-forming subject.

[0117] The term "non-stone forming subject" means that the subject has a low or zero tendency to form stones in the urine due to environmental conditions in said urine and due to any other more complex reasons (genetic background, diet, etc.).

[0118] Therefore, in addition to determining S-methyl-L-ergothioneine, or determining the amount of S-methyl-L-ergothioneine and L-ergothioneine, with the ORP assay, additional reliable information on the diagnosis or prognosis of the disease is obtained by detecting subjects with a higher tendency to form stones. This information is then useful for the recommendation or decision to start appropriate therapeutic intervention.

[0119] The present invention also relates to the use of ORP as a single diagnostic or prognostic marker for kidney disease, more particularly kidney stones or aminoaciduria, even more particularly cystine stones or cystinuria. Thus, the present invention includes an in vitro method for the diagnosis or prognosis of kidney disease, which comprises determining the redox potential in an isolated sample, particularly urine, of a subject. In a more specific embodiment of the method, the ORP of the isolated sample is then compared with a reference value, as described above, to classify the subject as a non-stone forming subject or as a stone forming subject.

[0120] The in vitro method of the invention provides diagnostic and / or prognostic information. In one embodiment, the method of the invention further comprises the steps of: (i) collecting diagnostic and / or prognostic information, and (ii) storing the information in a data carrier.

[0121] In the sense of the present invention, "data carrier" should be understood as any device, such as paper, containing meaningful information data for differential diagnosis and / or prognosis of kidney stones and amino aciduria. Carrier can also be any entity or device capable of carrying prognostic data. For example, carrier can include storage medium, such as ROM, such as CD ROM or semiconductor ROM, or magnetic recording medium, such as floppy disk or hard disk. In addition, carrier can be a transmittable carrier, such as electrical or optical signal, which can be transmitted via cable or optical cable or by radio or other devices. When diagnosis / prediction data are embodied in a signal that can be directly transmitted by cable or other equipment or device, carrier can be composed of such cable or other equipment or device. Other carriers relate to USB devices and computer archives. Examples of suitable data carriers are computer archives in paper, CD, USB, PC, or sound registration with the same information.

[0122] The present invention also provides a method for treating a patient suffering from kidney stones or aminoaciduria, particularly cystinuria, the method comprising the following steps:

[0123] (a) determining the amount of S-methyl-L-ergothioneine, and optionally the amount of L-ergothioneine, in an isolated test sample of a subject, and calculating the ratio between the amounts of S-methyl-L-ergothioneine and L-ergothioneine;

[0124] (b) comparing the amount or ratio determined in (a) with a reference value; and

[0125] (c1) wherein if the level determined in (a) is below a reference value for a subject not suffering from kidney stones or aminoaciduria, or (c2) wherein if the level determined in (a) is within the reference value range for a subject suffering from kidney stones or aminoaciduria, administering a pharmaceutically effective amount of a cystine solubilizing agent to a subject in need thereof.

[0126] The present invention also provides a method for treating a patient suffering from kidney stones or aminoaciduria, the method comprising the following steps:

[0127] (a) determining the amount of S-methyl-L-ergothioneine, and optionally the amount of L-ergothioneine, in an isolated test sample of a subject, and calculating the ratio between the amounts of S-methyl-L-ergothioneine and L-ergothioneine;

[0128] (b) comparing the amount or ratio determined in (a) with a reference value; and

[0129] (c1) wherein if the level determined in (a) is below a reference value, the reference value being a subject not suffering from kidney stones or aminoaciduria, or (c2) wherein if the level determined in (a) is within the reference value range for subjects suffering from kidney stone disease or aminoaciduria, administering a pharmaceutically effective amount of ergothioneine to a subject in need thereof.

[0130] As previously mentioned, the present inventors have also developed an effective and safe treatment for aminoaciduria and related kidney stones.

[0131] In certain embodiments of ergothioneine used as described above, optionally in combination with any of the embodiments provided above or below, the kidney stones are cystine stones.

[0132] In another specific embodiment of ergothioneine used as described above, optionally in combination with any embodiment provided above or below, the aminoaciduria is cystinuria.

[0133] In the specific embodiment of ergothioneine used as described above, optionally in combination with any embodiment provided above or below, ergothioneine is administered together with one or more pharmaceutically acceptable excipients and / or carriers in the form of a pharmaceutical composition. In a more specific embodiment, the pharmaceutical composition is an oral pharmaceutical composition.

[0134] In a specific embodiment optionally combined with any embodiment provided above or below, ergothioneine is administered at a dosage of 0.01-500 mg / kg body weight / day. In a more specific embodiment, the dosage is 0.05-300 mg / kg body weight / day. In an even more specific embodiment, the dosage is 0.1-200 mg / kg body weight / day.

[0135] As described above, the present invention also provides ergothioneine for use in combination therapy with a compound selected from other cystine solubilizers, L-cystine dimethyl ester, L-cystine methyl ester, L-cystine diamide, lipoic acid and combinations thereof for treating and / or preventing kidney stones or aminoaciduria.

[0136] All embodiments of ergothioneine for the above-described uses also apply to ergothioneine used in combination therapy.

[0137] In a specific embodiment of ergothioneine as defined above for use in combination therapy, optionally in combination with any embodiment provided above or below, the additional cystine solubilizer is selected from: penicillamine, tiopronin, captopril and bucillamine. In a more specific embodiment, the cystine solubilizer is selected from penicillamine and tiopronin.

[0138] In a particular embodiment of ergothioneine for combination therapy as defined above, ergothioneine is administered simultaneously, sequentially or separately with a compound selected from other cystine solubilizers, L-cystine dimethyl ester, L-cystine methyl ester, L-cystine diamide, lipoic acid and combinations thereof.

[0139] In particular embodiments of the use of ergothioneine as described above, optionally in combination with any embodiment provided above or below, the ergothioneine is L-ergothioneine.

[0140] Therefore, in a specific embodiment optionally combined with any embodiment provided above or below, the present invention provides L-ergothioneine for treating and / or preventing kidney stones or aminoaciduria. More particularly, L-ergothioneine is used to treat and / or prevent cystine calculi or cystinuria.

[0141] Throughout the description and claims, the word "comprise" and variations of the word are not intended to exclude other technical features, additives, components or steps.

[0142] In addition, the word "comprising" covers the case of "consisting of". Other objects, advantages and features of the present invention will become apparent to those skilled in the art after reading this specification, or may be learned through practice of the present invention. The following examples and drawings are provided as illustrations, and they are not intended to limit the present invention. The reference numerals associated with the drawings and placed in parentheses in the claims are only used to try to increase the intelligibility of the claims and should not be interpreted as limiting the scope of the claims. In addition, the present invention covers all possible combinations of the specific and preferred embodiments described herein. DETAILED DESCRIPTION

[0143] Example 1: Urinary markers of cystine stones in a cystinuria mouse model

[0144] method

[0145] Mouse care

[0146] All animal protocols were approved by the Animal Experiment Ethics Committee of IDIBLELL (AAALAC accredited institution, B9900010) and were performed by the corresponding Generalitat de Catalunya department in accordance with EU Directive 2010 / 63 / EU. The experiments were conducted with the highest scientific, humanistic and ethical principles. All animals were pure genetic background C57BL / 6J and maintained a 12-hour light-dark cycle in a humidity and temperature controlled room. The animals were housed in sterile cages with free access to food (Teklad Global 14% protein diet, Harlan Laboratories) and water.

[0147] In a mouse model of type B cystinuria (Slc7a9 - / - )

[0148] Slc7a9 - / - (mouse model of cystinuria) and S1c22a4 - / - Single loss-of-function mouse models (Feliubadalo et al., "Slc7a9-deficient mice develop cystinuria non-l andcystine urolithiasis" Hum Mol Genet 2003; vol 12; pp. 2097-2108; Kato Y. et al., "Gene knockout and metabolome analysis of carnitine / organic cation transporter OCTN1", Pharm. Res., 2010; vol 27, pp. 832-40) were crossed to obtain double heterozygous mice, which were backcrossed to obtain three expected genotypes, including double KO Slc7a9 - / - S1c22a4 - / - (dKO).

[0149] For genotyping analysis, genomic DNA was isolated from tail tissue. S1c22a4 was confirmed by PCR based on a 3'-primer strategy that allows differentiation of genotypes by generating 255 bp and 313 bp fragments from wt and KO alleles, respectively (F: 5'-gggtgtggtccagaggact-3', SEQ ID NO: 1; R wt-specific: 5'-tagttgccagccatctgttg-3', SEQ ID NO: 2; R KO-specific: 5'-gactgacataccattgaagc-3', SEQ ID NO: 3). - / - Genotype (30 cycles at 60°C annealing temperature). - / - The genotypes were confirmed by PCR based on a 3′-primer strategy that allowed the differentiation of genotypes by generating 452 bp and 311 bp fragments from the wt and KO alleles, respectively (F: 5′-gcattcgccacaggctcttc-3′, SEQ ID NO: 4; R-wt: 5′-ctgtgttggccagcacagac-3′, SEQ ID NO: 5; R KO-specific: 5′-cgcagcgcatcgccttctat-3′, SEQ ID NO: 6).

[0150] Sample collection

[0151] Mice from each genotype were housed separately in metabolic cages for 4 days, with the first day as an adaptation period. Mouse body weight, water and food intake, and feces and urine excretion were monitored every day. 24h urine samples were collected and stored at -80 °C until further analysis with 50 μL of thymol 10% in isopropanol as a preservative. Blood was obtained by intracardiac puncture with an EDTA-coated syringe and transferred to a micro tube EDTA-tube (Sarstedt), and centrifuged at 3000rpm for 10 minutes at 4 °C in a microcentrifuge after incubation for 10 minutes at room temperature. Then, plasma was separated into a new tube and kept on ice. Then, the plasma absorbance at 414nm was measured to quantitatively hemolyze with a NanoDrop spectrophotometer, and only those with OD<0.2 were considered for further analysis. Plasma samples were stored at -80 °C and centrifuged red blood cells (RBC) were also collected and stored at -80 °C.

[0152] Determination of L-Erg and S-Met-L-Erg in plasma, blood and erythrocytes

[0153] L-Erg was measured in plasma and erythrocytes as described in Sotgia S. et al. “Plasma L-ergothioneine measurement by high-performance liquid chromatography and capillary electrophoresis after a pre-column derivatization with 5-iodoacetamidofluorescein (5-IAF) and fluorescence detection”. Antopolsky M, ed. PLoS One 2013; vol. 8: e70374, and plasma creatinine was measured as described in (Zinellu A. et al., “Assay for the simultaneous determination of guanidinoacetic acid, creatinine and creatine in plasma and urine by capillary electrophoresis UV-detection”, J. Sep. Sci., 2006).

[0154] For plasma ergothioneine determination, 100 μL of acetonitrile was added to 100 μL of sample, and after vigorous vortex mixing, centrifuged at room temperature for 10 minutes at 17000×g. 50 μL of a solution consisting of 5-iodoacetylaminofluorescein (770 μmol / L) and sodium phosphate dodecahydrate (150 mmol / L) was added to 150 μL of clear supernatant, with a pH of 13. After vigorous vortex mixing, the reaction mixture was placed in a light-protected area at room temperature for 30 minutes. Finally, the sample was diluted 50 times and analyzed by capillary electrophoresis coupled to a laser-induced fluorescence detector.

[0155] For erythrocyte ergothioneine determination, 100 μL of water was added to 100 μL of erythrocytes and mixed thoroughly by vigorous vortex mixing; then, 400 μL of acetonitrile was added and mixed thoroughly by vortex mixing for 5 min. After centrifugation at 17000×g for 10 minutes at room temperature, 2 μL of the clarified supernatant was analyzed by ultra-high performance liquid chromatography coupled to a photodiode array detector set at 262 nm. For plasma creatinine measurement, the samples were filtered at 3000×g for 5 minutes on a microcon-10 device and then directly analyzed by capillary electrophoresis coupled to a photodiode array detector set at 190 nm.

[0156] Analysis of compound concentrations in urine

[0157] Creatinine concentrations in thawed urine samples were determined using a creatinine assay kit (Sigma) following the manufacturer's instructions after filtration through a 10 kDa MWCO spin filter (Amicon Ultra 0.5 mL, Millipore).

[0158] For L-Erg and S-met-L-Erg analysis in urine, thawed urine samples were centrifuged at 1000xg for 5 minutes at 4°C to remove any debris. The supernatant was then diluted 1 / 10 in Milli-Q water supplemented with deuterated L-Erg and S-met-L-Erg (final concentration of 50 ng / mL each). The samples were then filtered through an eXtremeFV PVDF 0.2 μm filter bottle (Thomson Instrument Company) and L-Erg and S-met were quantified by UPLC-MS / MS. LC-MS / MS was performed using a Dionex LPG-3400SD LC system coupled to a Thermo LTQ-XL ESI tandem mass spectrometer. The samples were kept at 15°C in an autosampler. 20 μl of diluted samples and standards were injected into a ZORBAX Eclipse Plus C18 (3.5 pm, 75×4.6 mm; Agilent) maintained at 35° C. Solvent A was 0.05% formic acid in ultrapure water, and solvent B was acetonitrile in 0.05% formic acid.

[0159] The reaction was carried out under isocratic conditions (99% A:1% B) at a flow rate of 0.9 ml / min for 3 minutes.

[0160] Mass spectrometry was performed in positive ion, electrospray ionization mode, using multiple reaction monitoring (MRM) for quantification of specific target ions. The source voltage was set at 3.0 kV, and the capillary temperature was maintained at 375 ° C. The nitrogen sheath gas flow was 90 (au), the auxiliary gas flow was 10 (au), and the purge gas flow was 6 (au). Alphagaz 2 helium (air liquid) was used as collision gas. The precursors of the product ion transitions of each compound are as follows: ergothioneine: 230.0→186.0; d3-ergothioneine 233.0→189.0; S-methyl-ergothioneine: 244.0→200.0; D3-S-methylergothioneine: 247.0→203.0. In all cases, the isolation width (m / z) and CID collision energy were 2.0 and 20%, respectively.

[0161] result

[0162] Gender and age differences in L-Erg concentrations in blood and urine

[0163] The inventors first analyzed wt and Slc7a9 - / -L-Erg levels in blood and urine of male mice were analyzed to look for differences that could be explained by differential expression. L-Erg concentrations in blood, plasma, or red blood cells (RBCs) showed no significant differences between wt and cystinuric male mice, as concentrations in plasma and blood were not significantly different in Slc7a9 - / - =L-Erg concentrations in RBCs were higher than those in plasma (data not shown). Since L-Erg concentrations in RBCs were two orders of magnitude higher than those in plasma, and to account for the putative role of hemolysis in the determination of L-Erg in plasma, the contribution of hemolysis to plasma L-Erg concentrations was analyzed, and no correlation was found between the two variables (data not shown). Urinary concentrations of L-Erg were significantly higher in Slc7a9 mice than in Slc7a9 mice (data not shown). - / - Male mice also showed a non-significant increase ( Figure 1 ), but surprisingly, in Slc7a9 - / - In male mice, the concentration of S-met-L-Erg (a metabolite of L-Erg) is expressed in Slc7a9 - / - Male mice showed a significant decrease ( Figure 1 ). These results suggest that urinary S-met-L-Erg can be used as a biomarker for cystine stones.

[0164] Looking for any age-related differences as reported in humans, the inventors then investigated whether the above conditions hold at another age. At 3 months of age, no differences in L-Erg concentrations in blood, plasma, or RBCs were detected between wt and cystinuric male mice, but when comparing 6 months of age to 3 months of age, a significant two-fold increase in L-Erg concentrations in RBCs was detected for all mice (data not shown). Similarly, urinary L-Erg concentrations were also significantly higher at 6 months of age, and no differences in urinary concentrations of S-Met-L-Erg were detected in relation to age ( Figure 2 ).

[0165] To examine sex-related differences, the inventors then investigated the concentrations of L-Erg in blood and urine and S-Met-L-Erg in urine as described above. At 3 months of age, no sex-related differences were observed in the concentrations of L-Erg in blood, plasma, or RBC, except that the concentration of L-Erg in RBC was 33% lower (p=0.093) (data not shown). However, the urinary concentrations of S-Met-L-Erg were significantly lower in wt and Slc7a9 mice. - / - In female mice, the expression of Slc7a9 was significantly decreased by almost 2-fold. - / - A significant decrease in the concentration of this metabolite and a significant increase in L-Erg were detected in female wt mice (data not shown).

[0166] In contrast, in 6-month-old female cystinuric mice, significant sex-related changes in L-Erg concentrations were detected in blood, plasma, and RBCs. An almost 2-fold decrease was observed in blood and RBCs and a 30% decrease was observed in plasma. A similar situation was observed in the urine of female mice, where the concentration of S-Met-L-Erg decreased almost 2-fold, while the concentration of L-Erg decreased by about 30% ( Figure 3 ). In addition, the RBC concentration of L-Erg was reduced by 30% in female cystinuric mice, and the urinary concentration of S-Met-L-Erg was significantly lower in female cystinuric mice than in female wt mice by 30%.

[0167] Differences in urinary L-Erg concentrations associated with the presence of cystine stones

[0168] One of the hallmarks of cystinuria is the presence of cystine stones in cystinuric patients and mice. Therefore, the inventors analyzed the urinary concentrations of L-Erg and S-Met-L-Erg in 3-month-old and 6-month-old stone-forming and non-stone-forming cystinuric mice ( Figure 4 ). L-Erg urinary concentrations were significantly lower in early stone former (ESF) female mice ( Figure 4 A), while S-Met-L-Erg in 3-month-old ESF females ( Figure 4 A) and higher in ESF males at both ages ( Figure 4 AB, P = 0.062 for males at 3 months of age). Differences in L-Erg and S-Met-L-Erg between the two sexes at both ages could also be identified, with concentrations generally lower in females, except for L-Erg concentrations at 3 months of age ( Figure 4 AB). The inventors investigated whether the urinary concentration of S-Met-L-Erg could be used to distinguish the stone disease phenotype in mice by receiver-operator characteristic (ROC) curve and obtained an area under the curve of more than 0.65, indicating that S-met-L-Erg could be used as a stone disease biomarker.

[0169] Since S-Met-L-Erg is a subproduct of L-Erg metabolism, the inventors investigated whether the ratio of S-Met-L-Erg to L-Erg showed differences associated with the stone disease phenotype. Figure 5 As shown in Figure A, the ratio in stone former (SF) mice was usually significantly lower than that in non-stone former (NSF) mice by 2-3 times. Since this result was so clear, the inventors investigated whether the ratio of urinary concentrations of S-Met-L-Erg and L-Erg could be used to distinguish the stone disease phenotype in mice by receiver-operator characteristic (ROC) curve. Figure 5The area under the curve of more than 0.8 indicated the possibility of using this ratio as a biomarker for stone disease in cystinuric mice, as shown in B. The inventors wondered if there were any differences in the performance of this ratio according to age or sex, and it turned out to be very similar or slightly better in all cases.

[0170] The inventors also investigated whether there was a correlation between the size of cystine stones (measured as dry weight) and the ratio and observed a slight correlation between the two variables (r=0.28, p=0.084).

[0171] Because it has been shown that L-Erg is transported via OCTN1 (Slc22a4) and S1c22a4 - / - Mice lack L-Erg in their kidneys, so the inventors replaced S1c22a4 - / - Mice and Slc7a9 - / - Mice were crossed to generate double KO (Slc7a9 - / - S1c22a4 - / - ) to see if there were differences in the proportion of mice displaying a stone disease phenotype.

[0172] with Slc7a9 - / - As in mice, the percentage of female mice with stone disease was significantly higher than that of male mice for all S1c22a4 genotypes. - / - The percentage of mice with stone disease was 8% higher in those KO mice, indicating that OCTN1 is a genetic regulator of cystine stones in mice. This gene is also present in humans (NCBI Gene ID 6583, or UniProt KB database IDQ9H015, sequence version 3 of May 1, 2007), so it is likely that the same mechanism applies to this species. The striking result was that at 40 weeks of age, in addition to Slc7a9 - / - S1c22a4 + / - (heterozygous for S1c22a4), the percentage of stone-bearing females was higher than that of males, and at this age, the percentage of stone-bearing males showed no S1c22a4 genotype-related differences.

[0173] To better understand this result, the inventors analyzed the expression of Slc7a9 in 3-month-old rats in the cystinuria background. - / - ) in the urine of mice lacking OCTN1 (Slc22a4). - / - Similar L-Erg levels as in wt mice, but the amount of S-Met-L-Erg was higher in Slc7a9 - / - In mice, the expression of β-catenin was significantly decreased by 50% (P=0.0022). - / -Knockout of S1c22a4 in the background produces L-Erg in urine (for S1c22a4 + / - , P = 0.0382, for S1c22a4 - / - , P = 0.0138) and a significant decrease in the concentration of S-Met-L-Erg, among which the concentration of S-Met-L-Erg was below the limit of quantification of the method used.

[0174] As expected, S1c22a4 - / - Mice show a higher expression of S1c22a4 + / - The data suggest that another transporter may be involved in the absorption of L-Erg from the diet, but since the metabolite (S-Met-L-Erg) could not be detected in the urine, OCTN1 is required for the transport of L-Erg into cells.

[0175] Example 2: Treatment of cystine stones in a cystinuria mouse model

[0176] method

[0177] Mouse care was as described in Example 1.

[0178] L-Erg Treatment

[0179] The mice were administered three different treatments: for stone-affected mice, 1 month, 3 months (subchronic) and 6 months (chronic exposure). In all cases, L-Erg was administered in the drinking water.

[0180] For 1 month of treatment, 8 3 month old male and female mice were provided with 15 or 60 mg / L of L-Erg for 4 weeks in standard cages with free access to water and food.

[0181] To evaluate the effect of L-Erg on mice with stone disease, 15 mice (8 males and 7 females) were treated with 60 mg / L L-Erg in drinking water, and 13 mice (4 males and 9 females) were not treated as controls. The mice were 10.9-26-9 weeks old at the beginning of the treatment period, with the mean age of the control and L-Erg treated groups being 15.3±1.4 and 16.9±1.01 weeks, respectively. During the 3-month treatment period, water intake and mouse body weight were monitored weekly.

[0182] For chronic exposure (6 months treatment), 4-6 mice per cage were treated for 6 months starting from weaning. To control the L-Erg dose, water intake and mouse body weight were monitored, and the L-Erg concentration in the drinking water was adjusted to obtain a daily dose of 16 mg / kg every 3 days in the first month and weekly thereafter. In the last week of treatment, all mice were individually caged in metabolic cages to collect urine, where water intake and mouse body weight were monitored daily.

[0183] In vivo X-ray imaging for detection of cystine stones

[0184] Isoflurane-anesthetized mice were subjected to X-ray imaging for stone disease detection and follow-up was performed with IVIS Lumina XRSeries III (Caliper Lifescience-Vertex Techniques) at the ages indicated in the corresponding figure legends following the manufacturer's imaging parameters with a calibration curve of cystine stones of known weight. Stone quantification was performed by manual delineation of the stone area using the dynamic imaging software provided with the instrument, and the estimated weight was interpolated from the calibration curve.

[0185] For growth rate analysis, when more than 2 data points were available, a linear regression model was used. The slope of the regression line in the model was used as the growth rate.

[0186] Sample collection

[0187] In the last week of any treatment period, mice were housed individually in metabolic cages for 4 days, with the first day as an adaptation period. Mouse body weight, water and food intake, and urine excretion were monitored daily. 24h urine samples were collected and stored at -80°C until further analysis with 50 μL of thymol 10% in isopropanol as a preservative. pH was measured with a pH meter (cat. no. 5209, Crison), and redox potential was measured at room temperature on a micropH 2000 (Crison) with an ORP electrode (cat. no. 5265, Crison).

[0188] On the last day, mice were anesthetized with isofluorane, blood was removed by intracardiac puncture, and kidneys were collected, weighed, and stored at -80°C until further use. If cystine stones were present, they were removed, dried, weighed, and stored at room temperature.

[0189] Analysis of compound concentrations in urine

[0190] Creatinine concentrations in thawed urine samples were determined using a creatinine assay kit (Sigma) specified by the manufacturer after filtration through a 10 kDa MWCO spin filter (Amicon Ultra 0.5 mL, Millipore).

[0191] L-Erg and S-Met-L-Erg analysis in urine was determined as described in Example 1. To determine the concentration of transsulfuration pathway metabolites, frozen kidneys were ground on dry ice using a pre-cooled mortar and pestle. Then, 100 mg of powdered kidney was homogenized in 400 μL PBS supplemented with 10 mM NEM. To induce protein precipitation, 4% PCA was added and the samples were centrifuged at 10,000 rpm in a microcentrifuge for 15 minutes at 4°C. The supernatant was transferred to a new tube and stored at -80°C until further analysis. The intracellular content of transsulfuration pathway metabolites was determined by UPLC-MS / MS (Escobar J, et al. Development of a reliable method based on ultra-performance liquid chromatography coupled to tandem massspectrometry to measure thiol-associated oxidative stress in whole blood samples. J. Pharm. Biomed. Anal. 2016; 123: 104-112). The protein pellet was resuspended in 400 μL 1 M NaOH and the supernatant was used to determine the total protein concentration by BCA protein assay kit (Thermo Scientific).

[0192] L-Erg-Cys in vitro binding assay

[0193] The reactivity of L-Erg with itself and with Cys was determined in vitro for 17 hours at room temperature in 0.2 M Na2HPO4 at pH = 7.2 and boric acid buffer (ref. 33650-1L, Fluka) at pH = 11. The presence of L-Erg-L-Erg and L-Erg-Cys dimers and cystine was determined by LC / MS-MS.

[0194] Statistical analysis

[0195] Nonparametric analysis (Wilcoxon-Mann-Whitney test) was used to assess significance using Rstudio. Statistical significance was considered positive if p < 0.05.

[0196] result

[0197] First, the optimal working dose for treating mice was determined by studying the effects of 1 month of L-Erg treatment at two different concentrations (15 and 60 mg / L) in drinking water on water intake and urine pH and ORP as well as L-Erg concentrations. The following observations were made:

[0198] i) Statistically non-significant increase in any of the tested L-Erg concentrations in water uptake normalized by surface at the end of treatment (p=0.11 and p=0.08, respectively) ( Figure 6 A), especially in females (sex data not shown); ii) a statistically significant increase in pH at 60 mg / L ( Figure 6 B), and a statistically non-significant increase in pH at 15 mg / L (p=0.052), especially in males (data not shown); iii) a statistically non-significant decrease in urine redox state or potential (ORP) ( Figure 6 c); and iv) statistically significant increases in urinary L-Erg and S-Met-L-Erg concentrations (respectively Figure 6 D and 6E). Interestingly, differences in urinary concentrations of L-Erg and S-Met-L-Erg were found between the two test conditions. At 15 mg / L, L-Erg and S-Met-L-Erg concentrations increased 3-fold (3.4±0.4) and 6-fold (5.9±0.6), respectively. At 60 mg / L, the increases in L-Erg and S-Met-L-Erg were 175-fold (174.6±38.4) and 15-fold (14.7±1.9), respectively. These differences suggest that at 60 mg / L, the endogenous pool and metabolism of L-Erg may be close to saturation. In order to maximize the amount of L-Erg available in the urine, an L-Erg concentration of 60 mg / L in the drinking water was taken for further determinations, which corresponded to a mean±SEM calculated dose of 13.6±1.6 mg / kg / day (data not shown).

[0199] L-Erg treatment did not alter cystine stone growth (3 months)

[0200] The effect of L-Erg treatment (60 mg / L in drinking water) on the development of cystine stones in stone-forming mice was first examined by monitoring cystine stone growth in treated and untreated mice monthly by X-ray over a 3-month period. No effect of treatment on cystine stone growth was observed under the conditions tested (p=0.61)( Figure 7). Since cystinuric mice can have multiple or single stones, it was also analyzed whether there was an effect on each type. No statistically significant effect was observed for either single or multiple stones (p=0.78 and p=0.41, respectively; data not shown). In order to observe the effect of the treatment on different metabolic parameters, the effect on urine pH and redox state as well as surface-corrected water uptake was also analyzed, and no differences were observed in L-Erg treated animals before and after treatment (data not shown). The estimated mean ± SEM L-Erg dose during the experiment was (17.24 ± 0.69 mg / kg / day).

[0201] L-Erg treatment prevents or delays the onset of cystine stones (Erg treatment for 6 months)

[0202] Then, whether L-Erg has any effect on cystine stone formation was tested by treating cystinuric mice 6 months after weaning. Taking into account previous experiments on adult mice, a target dose of 16 mg / kg / day was set. To allow the mice to grow, mouse growth and water intake were monitored throughout the experiment and L-Erg concentrations in drinking water were adjusted, taking into account water intake corrected by body surface according to the results of Tordoff et al. (see Tordoff MG, Bachmanov AA, Reed DR. Forty mouse strain survey of water and sodium intake. Physiol. Behav. 2007; 91: 620-31). The mean ± SD dose estimated during the 6-month period was 16.25 ± 6.29 (data not shown). To analyze the effect on the onset of stone disease, X-ray imaging of treated and untreated mice was performed monthly during the 6-month treatment period. A 50% reduction in the number of stone-forming mice and a delayed onset of stone disease ( Figure 8 A) (data not shown) and L-Erg treated groups showed almost statistically significant reduction in stone growth ( Figure 8 B).

[0203] To analyze the effect of long-term treatment, urine pH and redox potential were measured, and no difference in urine pH was observed ( Figure 8 C), and a statistically significant greater urine reduction was observed in L-Erg treated mice ( Figure 8 D) This chronic treatment showed no effect on water intake or mouse body weight (data not shown).

[0204] L-Erg increases the intracellular renal concentrations of components of the transsulfuration pathway

[0205] The antioxidant capacity of L-Erg could explain the reduction in urinary redox potential, but it does not by itself explain the reduced stone disease and the differences observed in stone growth rate between the two different treatments performed. In order to understand the mode of action of L-Erg on cystine stones, the formation of the dimer L-Erg-Cys was first analyzed in vitro by LC / MS-MS under two conditions, pH=7.2 and pH=11 (data not shown). Neither L-Erg-Cys nor L-Erg-L-Erg dimers were detected, indicating that the mode of action of L-Erg does not imply a reduction in L-Cys concentration by quenching a portion of it.

[0206] The lower ratio between the urinary concentrations of S-Met-L-Erg (L-Erg metabolite) and L-Erg in cystic compared to non-stone-forming mice (see data in Example 1) clearly indicates the involvement of intracellular mechanisms in cystine stones. In this sense, L-Erg has been reported to activate glutathione (GSH) synthesis by upregulating Nrf2 (Kerley RN, et al. The potential therapeutic effects of ergothioneine in pre-eclampsia. Free Radio. Biol. Med. 2018; 117: 145-157) and, in a proteomic approach to identify differential protein expression between cystinuric and wt mice, some enzymes involved in GSH synthesis such as Anpep (Anpe), Gpx1 (Gpx1) and Gstt1 (Gstt1) and cystine metabolism such as Cdo1 (Cdo1) have been shown to be downregulated in the renal brush border of cystinuric mice. Based on this, the intracellular content of those metabolites of the transsulfuration pathway was analyzed in the kidneys of chronically treated and untreated mice. Fig. 9 As shown in (AL), the intracellular concentrations of GSH (1.4x), Cys (1.6x), γ-glutamylcysteine ​​(1.7x) and Met (1.7x) increased significantly by about 1.5 times, and the intracellular concentrations of cystine (11.1x) and S-adenosylhomocysteine ​​(SAH) (1.2x) were significantly decreased in L-Erg treated mice. Interestingly, the GSH / GSSG, Cys / CssC and SAM / SAH ratios increased in L-Erg treated mice (2.1, 6.1 and 1.8 times, respectively). GSSG is oxidized glutathione; CssC is cystine; SAM is S-adenosylmethionine.

[0207] discuss

[0208] It is believed that the drug delivery system chosen is not well suited for controlling the dose. More variability is indeed suggested, but since L-Erg blood and plasma concentrations remained significantly higher for 6 weeks, and urine concentrations persisted for 1 week after the end of administration equivalent to 5 mg / kg·day, it is difficult to argue that a reduction in the dose of L-Erg taken up by the mice could be responsible for the stone disease observed in the treated animals.

[0209] In Slc7a9 - / - Preliminary results in mice have shown significantly different concentrations of metabolites of the transsulfuration pathway in the kidney. Those with reduced concentrations are: GSH (4.5x), GssG (17.9x), SAM (2.4x), Met (23.8x) and cystathionine (10.3x). Those with increased concentrations are Cys (6.7x), cystine (CssC, 3.8x), SAH (9x) and gamma-glutamylcysteine ​​(2.1x). The GSH / GssG and Cys / CssC ratios both increased by about 6 times in cystinuric male mice, while the SAM / SAH ratio decreased by 21 times. The data suggest that there is reduced methylation capacity of the kidney in cystinuria and reduced activity in the transsulfuration pathway in cystinuria. The unexpectedly elevated Cys content in the kidney may suggest a mechanism to compensate for the reduced GSH content in an effort to overcome the limitations that control any oxidative damage, as proposed by Banjac et al., "The cystine / cysteine ​​cycle: a redox cycle regulating susceptibility versus resistance to cell death"; 2008; Oncogene; vol. 27(11); pp. 1618-28. Chronic treatment with L-Erg has been shown to increase the expression of glutathione reductase, catalase, and superoxide dismutase in vascular endothelial human cells and to induce Nrf2 / ARE-mediated antioxidant genes in UVA-irradiated human keratinocytes. In this context, it was observed that the transsulfuration pathway was generally induced in L-Erg-treated mice, in addition to GssG, CssC, and SAH. Among others, the extent to which this increase in reducing capacity in the kidney is associated with a lower redox potential in the urine remains unknown and requires further experiments.

[0210] Unexpectedly, differences in the effect of L-Erg treatment on cystine stone development were observed between the two tested treatments: after stone onset or after prevention (before stone onset). Since the cystine stone growth rate in control mice was different between the two experiments (about 2 mg / day and about 3 mg / day, respectively), any statistical artifact cannot be completely excluded, because the amount of cystine stones that could be followed during the prevention experiment was low, or because of differences in cross-variability that could have a particular weight.

[0211] Example 3. Urinary Redox State or Potential (ORP) as a Prognostic Marker for Cystinuric Animals

[0212] The inventors realised that the urine ORP of cystinuric mice that did not form cystine stones was lower than that of mice that did form stones. Therefore, this parameter (measured as shown in Example 2) is also proposed for in vitro differential prognosis of cystinuric animals (including humans).

[0213] method

[0214] Mouse care was as described in Example 1.

[0215] Sample collection

[0216] Mice were housed individually in metabolic cages for 4 days, with the first day as an adaptation period. Mouse body weight, water and food intake, and urine excretion were monitored daily. 24h urine samples were collected and stored at -80°C until further analysis with 10mM sodium azide as a preservative. The redox potential in fresh urine was measured at room temperature using an ORP electrode (Orison) on a micropH 2000 (Orison).

[0217] result

[0218] ORP is higher in stone-forming mice

[0219] For cystinuria in the C57BL6 / J genetic background, the results from two different mouse models (Slc7a9 - / - (Feliubadalo et al., supra) or Slc3a1 D140G Urinary ORP was significantly higher in cystinuric mice with Slc3a1 D140G The model is disclosed in Peter et al., "A mouse model for cystinuria type I", Hum Mol Genet.-2003vol.1;12(17),pp.:2109-20. From the type I cystinuria mouse model 129S2 / SvPasCrl (Slc3a1 E383K ) showed similar results, considering the very limited amount of sporadic cystine stones produced by this model when measured. All these data are presented in Fig.10 The results clearly indicate that urinary ORP can be used for the diagnosis or prognosis of cystine stones. When both sexes were considered, although the trend was maintained in all groups, only Slc7a9 in C57BL6 / J - / - Male and Slc3a1 D140G Females showed a significant decrease in urinary ORP (sex data not shown).

[0220] Interestingly, the urine ORP in the non-stone former group of the 129S2 / SvPasCrl mouse model was significantly lower (p = 1.9e -09 )Slc3a1 D140G mouse models, although the same genes were affected in both models, suggesting the existence of genetic factors involved in urinary ORPs.

[0221] Citation List

[0222] Halperin EC et al., "The use of D-penicillamine in cystinuria:efficacyand untoward reactions", Yale J Biol Med., 1981, vol.54(6), pp.439-46.

[0223] Burtis CA et al., 2008, Chapter 14, section "Statistical Treatment of Reference Values".

[0224] Kato Y.et al., "Gene knockout and metabolome analysis of carnitine / organic cation transporter OCTN1", Pharm.Res., 2010; vol 27, pp.832-40.

[0225] Sotgia S.et al., "Plasma L-ergothioneine measurement by high-performance liquid chromatography and capillary electrophoresis after a pre-column derivatization with 5-iodoacetamidofluorescein(5-IAF)and fluorescence detection". Antopolsky M, ed.PLoS One 2013; vol.8:e70374

[0226] Zinellu A.et al.,“Assay for the simultaneous determination ofguanidinoacetic acid,creatinine and creatine in plasma and urine by capillaryelectrophoresis UV-detection”,J.Sep.Sci.,2006

[0227] Escobar J,et al.,“Development of a reliable method based on ultra-performance liquid chromatography coupled to tandem mass spectrometry tomeasure thiol-associated oxidative stress in whole blood samples$.J.Pharm.Biomed.Anal.2016;123:104-112 Tordoff MG,Bachmanov AA,Reed DR.Fortymouse strain survey of water and sodium intake.Physiol.Behav.2007;91:620-31

[0228] Kerley RN,et al.,The potential therapeutic effects of ergothioneinein pre-eclampsia.Free Radio.Biol.Med.2018;117:145-157

[0229] Feliubadalo et al.,“Slc7a9-deficient mice develop cystinuria non-land cystine urolithiasis”Hum Mol Genet 2003;vol 12;pp.2097-2108

[0230] Peter et al.,“A mouse model for cystinuria type I”,Hum Mol Genet.-2003 vol.1;12(17),pp.:2109-20.

[0231] Banjac et al.,“The cystine / cysteine cycle:a redox cycle regulatingsusceptibility versus resistance to cell death”;2008;Oncogene;vol.27(11);pp.1618-28.

Claims

1. Use of L-ergothioneine in preparing a medicine for treating and / or preventing kidney stones or aminoaciduria.

2. Use of L-ergothioneine in the preparation of a medicament for combined therapy with a compound selected from an additional cystine solubilizer, L-cystine dimethyl ester, L-cystine methyl ester, L-cystine diamide, lipoic acid and a combination thereof for treating and / or preventing kidney stones or aminoaciduria.

3. The use according to claim 1 or 2, wherein the kidney stones are cystine stones, or wherein the aminoaciduria is cystinuria.

4. purposes according to claim 1 or 2, wherein the L-ergothioneine is used together with one or more pharmaceutically acceptable excipients and / or carriers in the form of a pharmaceutical composition.

5. The method according to claim 1 or 2, wherein the L-ergothioneine is administered at a dosage of 0.01-500 mg / kg body weight / day.

6. Use of S-methyl-L-ergothioneine in the preparation of a reagent for diagnosing and / or prognosing a renal disease, wherein the renal disease is kidney stones or renal aminoaciduria.

7. Use of S-methyl-L-ergothioneine in the preparation of a reagent for a method for diagnosing and / or prognosing nephropathy, wherein the nephropathy is kidney stones or renal amino aciduria, and the method comprises the following steps: - determining the amount of S-methyl-L-ergothioneine in an isolated test sample from the subject; and - comparing the amount of S-methyl-L-ergothioneine in the subject with a reference value, wherein if the amount determined in the subject is lower than the reference value, which is a reference value for a healthy subject or a subject not suffering from any kidney disease, it indicates that the subject is suspected of suffering from the kidney disease.

8. The use according to claim 7, wherein the method further comprises the following steps: - determining the amount of L-ergothioneine in an isolated test sample of the subject, and - Calculate the ratio of the amount of S-methyl-L-ergothioneine to L-ergothioneine.

9. The use according to claim 6 or 7, wherein the kidney stones are cystine stones, or wherein the renal aminoaciduria is cystinuria.

Citation Information

Patent Citations

  • Methods for the preparation of organotin compounds

    EP0002019A1

  • Methods and compositions for diagnosis and prognosis of renal injury and renal failure

    CN103238068A

  • Biomarkers related to kidney function and methods using the same

    CN105209909A

  • Methods and compositions for diagnosis and prognosis of renal injury and renal failure

    CN107976547A

  • Use of bucillamine for the manufacture of a medicament for the treatment of cystinuria

    EP0551180A1